Previous 10 | Next 10 |
Organon was formed when pharma giant Merck spun out its Established Brands, Women's Health and Biosimilars divisions into a new entity. The deal enabled Merck to realise a $9bn tax windfall, and Organon initially looked fundamentally undervalued at a P/S ratio of <1.5x. Organon...
Biotechnology/Pharmaceuticals and Healthcare providers are undervalued relative to historical averages. Healthcare equipment is the most overvalued subsector. Fast facts on IYH. This monthly article series shows a dashboard with aggregate industry metrics in healthcare. ...
Baxter’s 8.7% 5-yr return on invested capital, ROIC, is quite a bit below its peers. TTM ROIC of 6.1% is about half the Industry ETF avg of 11.1%. Long-term debt ballooned from $5.8 billion at the end of 2020 to $17.1 billion as of March 2022. Goodwill assets also jumped t...
Daré will receive a $10 million upfront payment from Organon An estimated 21 million American women experience bacterial vaginosis SAN DIEGO, June 30, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE ), a leader in women’s health innovation, ...
DON is a dividend mid-cap ETF with a monthly distribution. 23% of asset value is in financials. Past performance shows no edge over a mid-cap benchmark. For further details see: DON: Mid-Cap Dividend ETF Review
The pharmaceutical/biotechnology subsector has the best value and quality scores. Healthcare equipment is the most overvalued industry. IHF: a concentrated ETF in healthcare providers. 10 stocks cheaper than their peers in June. For further details see: IHF: Healthca...
Organon's P/E ratio was 6.5 at the end of Q1 2022, significantly lower than the pharmaceutical industry average. Viatris' revenue was $4,191.7 million in the first quarter of 2022, down 5.4% from a year earlier. Viatris' generic and brand drug sales have been declining year on yea...
Unofficial sources said Joincare would seek to raise around $300 to $400 million. META Pharma of Shenzhen raised $15 million in Seed and Pre-A rounds to fund its immunometabolism-based small-molecule drug discovery operations. CANbridge, a Beijing-Cambridge MA rare disease/rare on...
Women’s health company Organon (NYSE:OGN) announced on Monday an agreement with Chinese biopharmaceutical company Shanghai Henlius Biotech, Inc. (OTCPK:SGBCF) for commercialization of two biosimilar candidates targeted at conditions such as breast cancer and osteoporosis. Pertuzumab is...
Collaboration expands and underscores commitment to biosimilars portfolio and focus on women’s health with biosimilar candidates for osteoporosis and breast cancer Organon (NYSE: OGN), a global women’s health company with deep expertise in biosimilar commercial...
News, Short Squeeze, Breakout and More Instantly...
VANCOUVER, BC / ACCESSWIRE / July 31, 2024 / (TSXV:OGN)(OTCQX:OGNRF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce a new significant gold-silver discovery, called the Navidad vein system, on the Ermitaño Mine concessions in Sonora, Mexico where the Company holds a...
VANCOUVER, BC / ACCESSWIRE / July 24, 2024 / (TSXV:OGN)(OTCQX:OGNRF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce updates for its partner funded exploration stage projects and royalties. Highlights Estimated 30,000 metres of drilling in seven planned or comp...
Company estimates $15 million of milestone expense in the second quarter Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, will release its second quarter 2024 financial results on August 6, 2024, prior to the company’s webcast and conference...